Modesto dad turns to medical marijuana to save son diagnosed with Dravet’s Syndrome

jason.jadonMODESTO, Calif. (KCRA) —Jason David from Modesto chronicles the ups and downs with his 6-year-old son Jayden, who was diagnosed with Dravet syndrome, on a Facebook page called Jason and Jayden’s Journey.

Jayden was diagnosed with Dravet, a rare form of epilepsy, when he was a baby. Since then, he has had seizures preventing him from walking, playing and living life.

“At one point Jayden had seizures 24 hours a day lasting an hour and a half,” David said. “I went to my doctor and said, ‘I don’t think Jayden is going to last, he can’t sleep, can’t eat, he hasn’t used the restroom, he can’t do anything.'”

David said his son has been taken away in an ambulance more than 40 times. He’s also taken 22 pills a day — 12 different kinds and none of them worked.

David said it got so bad that he wanted to kill himself and put a gun to his head.

But now, those thoughts are long gone.

As a last resort, David turned to medical marijuana. Specifically, a liquid form that contains a component known as CBD.

Jayden’s pediatrician prescribes it to Jayden and says the liquid form maintains medicinal qualities, while giving less of a high.

Jayden has been getting a few drops a day for the past two years and David said it’s been a remarkable difference.

Jayden is the most independent he’s ever been. He plays well, can walk and give his dad high fives, David said.

“(The) first day I gave him medical marijuana, thank God. (It was) the first day he went seizure free in his life,”he said.David said he wants to share his story to help other parents in the same situation.

He says parents need to educate themselves and do what’s right for their own children.

The father and son have been featured in numerous articles and television shows. Jason and Jayden will be featured as a small piece in a special about medical marijuana with Dr. Sanjay Gupta that airs Sunday on CNN.

Jayden’s pediatrician said he is seeing more children with autism and seizures who are benefiting from medical marijuana.

The doctor admits not a lot of studies have been done on medicinal marijuana, which is why doctors across the board may have differing opinions.

However, doctors at the University of California-San Francisco are now studying the affects the CBD component in medical marijuana has on epileptic children.

readbutton.pngRead more: http://www.kcra.com/news/local-news/news-modesto/modesto-dad-turns-to-medical-marijuana-to-save-son/-/12970436/21394696/-/frdj10/-/index.html#ixzz2fjai3tyH

Advertisements

Cured Too: A Cancer Story: A Film By David Triplett

Cured Too: A Cancer Story: A Film By David Triplett

This is a documentary of how myself and others cured our cancers using an alternative and controversial treatment: cannabis oil. It’s a proven fact that CBD and THC, two of many components in cannabis, shrink tumors and cure cancer. This documentary shows my cancer being cured and explores the history and politics of cannabis and cancer. You will also see samples of many antique cannabis medicine bottles.

Active Ingredient in Cannabis Kills Cancer Cells in Brain

LabNew research out of Spain suggests that THC — the active ingredient in marijuana — appears to prompt the death of brain cancer cells.

The finding is based on work with mice designed to carry human cancer tumors, as well as from an analysis of THC’s impact on tumor cells extracted from two patients coping with a highly aggressive form of brain cancer.

Explaining that the introduction of THC into the brain triggers a cellular self-digestion process known as “autophagy,” study co-author Guillermo Velasco said his team has isolated the specific pathway by which this process unfolds, and noted that it appears “to kill cancer cells, while it does not affect normal cells.”

Velasco is with the department of biochemistry and molecular biology in the School of Biology at Complutense University in Madrid. The findings were published in the April issue of The Journal of Clinical Investigation.

The Spanish researchers focused on two patients suffering from “recurrent glioblastoma multiforme,” a fast-moving form of brain cancer. Both patients had been enrolled in a clinical trial designed to test THC’s potential as a cancer therapy.

Using electron microscopes to analyze brain tissue taken both before and after a 26- to 30-day THC treatment regimen, the researchers found that THC eliminated cancer cells while it left healthy cells intact.

The team also was able, in what it described as a “novel” discovery, to track the signaling route by which this process was activated.

These findings were replicated in work with mice, which had been “engineered” to carry three different types of human cancer tumor grafts.

“These results may help to design new cancer therapies based on the use of medicines containing the active principle of marijuana and/or in the activation of autophagy,” Velasco said.

Outside experts suggested that more research is needed before advocating marijuana as a medicinal intervention for brain cancer.

Dr. John S. Yu, co-director of the Comprehensive Brain Tumor Program in the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai Medical Center in Los Angeles, said the findings were “not surprising.”

“There have been previous reports to this effect as well,” he said. “So this is yet another indication that THC has an anti-cancer effect, which means it’s certainly worth further study. But it does not suggest that one should jump at marijuana for a potential cure for cancer, and one should not urge anyone to start smoking pot right away as a means of curing their own cancer.”

But that’s exactly what many brain cancer patients have been doing, said Dr. Paul Graham Fisher, the Beirne Family director of Neuro-Oncology at Stanford University.

“In fact, 40 percent of brain tumor patients in the U.S. are already using alternative treatments, ranging from herbals to vitamins to marijuana,” he said. “But that actually points out a cautionary tale here, which is that many brain cancer patients are already rolling a joint to treat themselves, but we’re not really seeing brain tumors suddenly going away as a result, which we clearly would’ve noticed if it had that effect. So we need to be open-minded. But this suggests that the promise of THC might be a little over-hoped, and certainly requires further investigation before telling people to go out and roll a joint.”

By Alan Mozes

HealthDay Reporter
April 2

More information

For additional details on the risks and benefits of marijuana use as it relates to cancer, visit the National Cancer Institute or the American Cancer Society.

SOURCES: Guillermo Velasco, Ph.D., department of biochemistry and molecular biology, School of Biology, Complutense University, Madrid; John S. Yu, M.D., co-director, Comprehensive Brain Tumor Program, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles; Paul Graham Fisher, M.D., associate professor, neurology, pediatrics, and neurosurgery and human biology and the Beirne Family Director of Neuro-Oncology, Stanford University; April 2009, The Journal of Clinical Investigation

readbutton.png

Cannabidiol (CBD) “Turns Off” the Cancer Gene Involved in Metastasis Findings by Scientists at California Pacific Medical Center gives Scientific Support for Cannabis Science Initiatives

products_overviewNew studies by Scientists at California Pacific Medical Center, have shown that cannabidiol, (CBD), has the ability to “turn off” a gene that causes breast and other types of cancers to metastasize, according to the San Francisco Chronicle newspaper.

NBC News reports, “The drug “has been shown to reduce pain and nausea” in cancer patients. AIDS patients also use cannabis to eat, sleep and otherwise be more functional. Turns out that cannabidiol has none of the psychotropic effects of marijuana as a whole. The researchers hope to move to clinical trials on humans soon to test the cannabidiol inhibition of metastasis, reported in the San Francisco Chronicle. “What they found is that the cannabinoid turns off the overexpression of ID-1, which makes the cells lose their ability to travel to distant tissues. In other words, it keeps the cells more local and blocks their ability to metastasize. (spread to a new location) The researchers stressed cannabidiol works only on cancer cells that have these high levels of ID-1 and these do not include all cancerous tumors but, rather, aggressive, metastatic cells. But they’ve found such high levels in leukemia, colorectal, pancreatic, lung, ovarian, brain and other cancers.”

Cannabis Science appreciates this additional scientific support that this report provides for our two target drug development programs as the Company moves forward with CS-TATI-1, and based on the success of previous skin cancer patients who self-administered cannabis-based treatments, the Company is focusing on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.

Dr. Robert Melamede states, “Cannabis Science is excited for the increasing scientific support for our projects. In the near future, we will share new developments, as well a the progress we have made with our earlier defined initiatives. Our professional expansion and development, as detailed in our latest news releases,was driven by the science of how cannabinoids can benefit both HIV/AIDS and Cancer Patients.”

San Francisco Chronicle: http://www.sfgate.com/health/article/Pot-compound-seen-as-tool-against-cancer-3875562.php#page-1

About CS-S/BCC-1

Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas. Cannabis Science has already seen success with 4 self-medicated skin cancer patients. These patients have been self-administering using cannabis-based extracts applied topically to their carcinomas and tumors. These patients have experienced shrinking and apparent eradication of their skin cancer, backed by positive reports from their doctors, which is why the Company is confident about the eminent success of this new drug to be developed.

About CS-TATI-1

Data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2). Funding for the Mount Sinai study was provided by a National Institutes of Health (NIH) Clinical and Translational Science Award Grant. Cannabis Science’s research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1’s, PO1’s and SBIRS which exist to support preclinical development of target validation and proof of concept studies. Cannabis Science will be pursing implementation of these studies through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).

readbutton.png

Study Shows Cannabis Lowers Bladder Cancer Risk

featured-image

New research says smoking pot may lowers bladder cancer risk.

For the study, the researchers compared the risk of bladder cancer in more than 83,000 men who smoked cigarettes only, marijuana (cannabis) only, or both substances. The investigators found that men who only smoked pot were the least likely to develop bladder cancer over the course of 11 years.

“Cannabis use only was associated with a 45 percent reduction in bladder cancer incidence, and tobacco use only was associated with a 52 percent increase in bladder cancer,” said study author Dr. Anil A. Thomas, a fellow in urology at Kaiser Permanente Medical Center in Los Angeles.

Smoking both tobacco and marijuana raised the risk of bladder cancer, but less so than for those who only smoked tobacco, Thomas found. He presented the findings Monday at the American Urological Association annual meeting in San Diego.

Dr. Karim Chamie, an assistant professor of urology at the David Geffen School of Medicine at the University of California, Los Angeles, took issue with the fact that every man in the study smoked something, so there was no comparison to men who did not smoke at all.

“It’s hard to judge a study when the reference group is not nonsmokers,” Chamie said. And the number of bladder cancers diagnosed in the study seemed low, he added, especially because everyone smoked something and smoking tobacco is considered a leading risk factor for the disease.

“We know smoking increases your risk of bladder cancer by two- or threefold,” Chamie noted.

Also, the men in the study weren’t representative of the entire United States, Chamie said, noting all were insured residents of California.

Thomas said his research team wasn’t looking at all age groups and was not collecting data on lifetime prevalence.

Thomas stressed that he’s not condoning or recommending marijuana as a way to affect risk of bladder cancer. The value of the study may be to spur other research into new treatments for bladder cancer, he said.

The men in the study, aged 45 to 69, were patients at Kaiser Permanente in California. Thomas and his team evaluated data on their lifestyle habits, including tobacco and marijuana smoking, between 2002 and 2003.

The researchers cross-referenced the study data with medical records to see who was diagnosed with bladder cancer. They omitted men with a history of bladder cancer.

Overall, 41 percent of the men reported marijuana use, 57 percent said they used tobacco and 27 percent reported using both.

During 11 years of follow-up, 279 men — 0.3 percent — were diagnosed with bladder cancer. Eighty-nine pot smokers (0.3 percent) developed bladder cancer compared to 190 (0.4 percent) who did not smoke pot.

More frequent marijuana use — smoking pot more than 500 times — was associated with greater risk reduction than infrequent marijuana use — smoking once or twice, the researchers found.

Thomas said that while the study saw a link between smoking marijuana and lower bladder cancer risk, compared to tobacco smokers, it did not prove a cause-and-effect relationship. He couldn’t explain the link, but speculated on the possible mechanism.

“The theory is that there are receptors in the bladder that are affected by cannabis,” he said. The cannabinoids [compounds] in the marijuana may link with the cannabinoid receptors in the bladder and somehow protect against cell changes that can lead to cancer, he said.

A man’s lifetime risk of bladder cancer is almost 4 percent, according to the American Cancer Society. This means about one in 26 men will develop bladder tumors.

The study was funded by the Kaiser Permanente Research and Evaluation Center. Findings and conclusions of research presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.

SOURCES: Anil A. Thomas, M.D., endourology fellow, Kaiser Permanente Medical Center, Los Angeles; Karim Chamie, M.D., assistant professor, urology, Jonsson Comprehensive Cancer Center and David Geffen School of Medicine, University of California Los Angeles; May 6, 2013, presentation, American Urological Association annual meeting, San Diego

readbutton.png

Cannabis Compound (CBD) May Beat Antipsychotics at Treating Schizophrenia

By  Associate News Editor

Reviewed by John M. Grohol, Psy.D. on June 7, 2012

arizona-medical-marijuana-testing-cbd

A certain marijuana compound known as cannabidiol (CBD) can treat schizophrenia as well as antipsychoticdrugs, with far fewer side effects, according to a preliminary clinical trial.

The research team, led by Markus Leweke of the University of Cologne in Germany, studied 39 people with schizophrenia who were hospitalized for a psychotic episode. Nineteen patients were treated with amisulpride, an antipsychotic medication that is not approved in the U.S., but is similar to other approved drugs.

The remaining 20 patients were given CBD, a substance found in marijuana that is considered responsible for the mellowing or anxiety-reducing effects. Unlike the main ingredient in marijuana, THC, which can trigger psychotic episodes and worsen schizophrenia, CBD has antipsychotic effects, according to prior research in both animals and humans.

Neither the patients nor the scientists knew who was receiving which drug. At the end of the four-week trial, both groups made significant clinical improvements in their schizophrenic symptoms, and there was no difference between those getting CBD or amisulpride.

“The results were amazing,” said Daniel Piomelli, Ph.D., professor of pharmacology at the University of California-Irvine and a co-author of the study. “Not only was [CBD] as effective as standard antipsychotics, but it was also essentially free of the typical side effects seen with antipsychotic drugs.”

Antipsychotic drugs may cause devastating and sometimes permanent movement disorders; they can also lower a patient’s motivation and pleasure. The new generation of these drugs can also lead to weight gain and increase the risk for diabetes. These side effects are well known as a major hindrance during treatment.

In the German study, weight gain and movement problems were observed in patients taking amisulpride, but not CBD.

“These exciting findings should stimulate a great deal of research,” said Dr. John Krystal, chair of psychiatry at Yale University School of Medicine, who was not associated with the research. He notes that CBD not only had fewer side effects, but also seemed to work better on schizophrenia’s so-called “negative symptoms,” which are notoriously hard to treat.

Negative symptoms of schizophrenia include social withdrawal, a lowered sense of pleasure and a lack of motivation. However, since current antipsychotic medications can actually cause these negative symptoms, it wasn’t clear whether CBD was better than amisulpride at getting rid of these symptoms, or whether CBD simply caused fewer side effects to begin with.

If replicated, the results suggest that CBD may be at least as effective as current medications for the treatment of schizophrenia, without the severe side effects that make patients reluctant to take medication.

“The real problem with CBD is that it’s hard to develop for a variety of silly reasons,” said Piomelli. Since it comes from marijuana, there are obvious political issues surrounding its use. Extracting it from the plant is also expensive.

But the biggest obstacle may be that CBD is a natural compound, and therefore can’t be patented the way new drugs are. So although CBD could outsell the current blockbuster antipsychotic drugs, pharmaceutical companies aren’t likely to develop it. Researchers are working to develop synthetic versions of CBD that would avoid such hurdles.

“We have one and are hoping to move forward in the near future,” Piomelli said.

The study is published online in the journal Translational Psychiatry.

Source:  University of Cologne

readbutton.png

Mutations Found in Individuals With Autism Interfere With Endocannabinoid Signaling in the Brain

inhibitory neuron whose function is affected by neuroligin mutation
inhibitory neuron whose function is affected by neuroligin mutation

Mutations found in individuals with autism block the action of molecules made by the brain that act on the same receptors that marijuana’s active chemical acts on, according to new research reported online April 11 in the Cell Press journal Neuron. The findings implicate specific molecules, called endocannabinoids, in the development of some autism cases and point to potential treatment strategies.

“Endocannabinoids are molecules that are critical regulators of normal neuronal activity and are important for many brain functions,” says first author Dr. Csaba Földy, of Stanford University Medical School. “By conducting studies in mice, we found that neuroligin-3, a protein that is mutated in some individuals with autism, is important for relaying endocannabinoid signals that tone down communication between neurons.”

When the researchers introduced different autism-associated mutations in neuroligin-3 into mice, this signaling was blocked and the overall excitability of the brain was changed.

“These findings point out an unexpected link between a protein implicated in autism and a signaling system that previously had not been considered to be particularly important for autism,” says senior author Dr. Thomas Südhof, also of Stanford. “Thus, the findings open up a new area of research and may suggest novel strategies for understanding the underlying causes of complex brain disorders.”

The results also indicate that targeting components of the endocannabinoid signaling system may help reverse autism symptoms.

The study’s findings resulted from a research collaboration between the Stanford laboratories of Dr. Südhof and Dr. Robert Malenka, who is also an author on the paper.

###

Neuron, Foldy et al.: “Autism-Associated Neuroligin-3 Mutations Commonly Disrupt Tonic Endocannabinoid Signaling.”

readbutton.png

readbutton.png